Compared with Trastuzumab alone, a combined regimen of Pyrotinib and Trastuzumab is equally safe, and more effective in regulating expression of COX-2, DcR3, and caspase-3, improving immune function, reducing the level of tumor markers, and improving tumor response in patients with HER-2 positive BC. The gene discussed is TNFRSF6B; the disease is breast cancer.